Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline Review, H2 2016’, provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)

The report reviews pipeline therapeutics for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics and enlists all their major and minor projects

The report assesses Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AnGes MG, Inc.

AstraZeneca Plc

Athera Biotechnologies AB

Athersys, Inc.

Bayer AG

Betagenon AB

BiogenCell Ltd.

CardioVascular BioTherapeutics, Inc.

Celgene Corporation

Diffusion Pharmaceuticals Inc

Hemostemix Ltd

ID Pharma Co., Ltd.

Juventas Therapeutics, Inc.

LipimetiX Development Inc

miRagen Therapeutics, Inc.

Nuo Therapeutics, Inc.

Proteon Therapeutics, Inc.

Recardio GmbH

Resverlogix Corp.

Sigma-Tau S.p.A.

Stemedica Cell Technologies, Inc.

Symic Biomedical, Inc.

Theravasc, Inc.

VESSL Therapeutics Ltd

ViroMed Co Ltd

Yuyu Pharma, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview 10

Therapeutics Development 11

Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview 11

Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis 12

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies 13

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies 19

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development 21

AnGes MG, Inc. 21

AstraZeneca Plc 22

Athera Biotechnologies AB 23

Athersys, Inc. 24

Bayer AG 25

Betagenon AB 26

BiogenCell Ltd. 27

CardioVascular BioTherapeutics, Inc. 28

Celgene Corporation 29

Diffusion Pharmaceuticals Inc 30

Hemostemix Ltd 31

ID Pharma Co., Ltd. 32

Juventas Therapeutics, Inc. 33

LipimetiX Development Inc 34

miRagen Therapeutics, Inc. 35

Nuo Therapeutics, Inc. 36

Proteon Therapeutics, Inc. 37

Recardio GmbH 38

Resverlogix Corp. 39

Sigma-Tau S.p.A. 40

Stemedica Cell Technologies, Inc. 41

Symic Biomedical, Inc. 42

Theravasc, Inc. 43

VESSL Therapeutics Ltd 44

ViroMed Co Ltd 45

Yuyu Pharma, Inc. 46

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment 47

Assessment by Monotherapy Products 47

Assessment by Target 48

Assessment by Mechanism of Action 50

Assessment by Route of Administration 52

Assessment by Molecule Type 54

Drug Profiles 56

ACP-01 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

AEM-28 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

ALD-301 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

alprostadil - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Annexin A-5 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

apabetalone - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

BAY-1193397 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

BC-1 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

beperminogene perplasmid - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

CVBT-141C - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

DVC-10101 - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

ELS-140 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

JVS-100 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

levocarnitine propionate hydrochloride - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

MGN-6114 - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

MultiGeneAngio - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

O-304 - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

PC-mAb - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

PDA-002 - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

PF-05285401 - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

REC-03 - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

Rejuveinix - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

rivaroxaban - Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

SB-030 - Drug Profile 124

Product Description 124

Mechanism Of Action 124

R&D Progress 124

sodium nitrite SR - Drug Profile 126

Product Description 126

Mechanism Of Action 126

R&D Progress 126

Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 128

Product Description 128

Mechanism Of Action 128

R&D Progress 128

transcrocetinate sodium - Drug Profile 134

Product Description 134

Mechanism Of Action 134

R&D Progress 134

TXA-127 - Drug Profile 138

Product Description 138

Mechanism Of Action 138

R&D Progress 138

V-10 - Drug Profile 141

Product Description 141

Mechanism Of Action 141

R&D Progress 141

VM-202 - Drug Profile 142

Product Description 142

Mechanism Of Action 142

R&D Progress 142

vonapanitase - Drug Profile 145

Product Description 145

Mechanism Of Action 145

R&D Progress 145

YY-984 - Drug Profile 149

Product Description 149

Mechanism Of Action 149

R&D Progress 149

zibotentan - Drug Profile 150

Product Description 150

Mechanism Of Action 150

R&D Progress 150

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects 152

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products 156

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones 157

Featured News & Press Releases 157

Oct 25, 2016: Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference 157

Oct 20, 2016: Dr. Jackie R. See M.D. Joins AngioSoma, Scientific Advisory Board 157

Oct 20, 2016: Proteon Therapeutics Appoints Paul Hastings Chairman of Its Board of Directors 158

Oct 11, 2016: AngioSoma Files 3 New Patent Applications on Liprostin 158

Oct 03, 2016: Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada 159

Sep 29, 2016: Low levels of endogenous anti-PC identified as a novel risk factor for vein bypass graft failure and cardiovascular complications in PAD patients 159

Sep 28, 2016: Athera presents positive First-in-Patient data with their new antibody against immunovascular disease at ESVS 160

Aug 11, 2016: Athera Biotechnologies completes First-in-Patient Study with New Antibody Against Immunovascular Disease 160

May 24, 2016: Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 161

Apr 13, 2016: Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease 162

Feb 04, 2016: Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease 162

Oct 12, 2015: Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015 163

Aug 13, 2015: Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease 164

Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor 165

Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease 165

Appendix 167

Methodology 167

Coverage 167

Secondary Research 167

Primary Research 167

Expert Panel Validation 167

Contact Us 167

Disclaimer 168

List of Tables

List of Tables

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2016 11

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Development by Companies, H2 2016 (Contd..1) 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Comparative Analysis by Unknown Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by AnGes MG, Inc., H2 2016 21

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by AstraZeneca Plc, H2 2016 22

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Athera Biotechnologies AB, H2 2016 23

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Athersys, Inc., H2 2016 24

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Bayer AG, H2 2016 25

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Betagenon AB, H2 2016 26

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by BiogenCell Ltd., H2 2016 27

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by CardioVascular BioTherapeutics, Inc., H2 2016 28

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Celgene Corporation, H2 2016 29

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 30

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Hemostemix Ltd, H2 2016 31

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by ID Pharma Co., Ltd., H2 2016 32

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Juventas Therapeutics, Inc., H2 2016 33

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by LipimetiX Development Inc, H2 2016 34

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by miRagen Therapeutics, Inc., H2 2016 35

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Nuo Therapeutics, Inc., H2 2016 36

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Proteon Therapeutics, Inc., H2 2016 37

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Recardio GmbH, H2 2016 38

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Resverlogix Corp., H2 2016 39

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Sigma-Tau S.p.A., H2 2016 40

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Stemedica Cell Technologies, Inc., H2 2016 41

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Symic Biomedical, Inc., H2 2016 42

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Theravasc, Inc., H2 2016 43

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by VESSL Therapeutics Ltd, H2 2016 44

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by ViroMed Co Ltd, H2 2016 45

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Yuyu Pharma, Inc., H2 2016 46

Assessment by Monotherapy Products, H2 2016 47

Number of Products by Stage and Target, H2 2016 49

Number of Products by Stage and Mechanism of Action, H2 2016 51

Number of Products by Stage and Route of Administration, H2 2016 53

Number of Products by Stage and Molecule Type, H2 2016 55

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Dormant Projects, H2 2016 152

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Dormant Projects (Contd..1), H2 2016 153

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Dormant Projects (Contd..2), H2 2016 154

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Dormant Projects (Contd..3), H2 2016 155

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Discontinued Products, H2 2016 156

List of Figures

List of Figures

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2016 11

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Assessment by Monotherapy Products, H2 2016 47

Number of Products by Top 10 Targets, H2 2016 48

Number of Products by Stage and Top 10 Targets, H2 2016 48

Number of Products by Top 10 Mechanism of Actions, H2 2016 50

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 50

Number of Products by Top 10 Routes of Administration, H2 2016 52

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 52

Number of Products by Top 10 Molecule Types, H2 2016 54

Number of Products by Stage and Top 10 Molecule Types, H2 2016 54

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports